JP2021523129A5 - - Google Patents
Info
- Publication number
- JP2021523129A5 JP2021523129A5 JP2020562156A JP2020562156A JP2021523129A5 JP 2021523129 A5 JP2021523129 A5 JP 2021523129A5 JP 2020562156 A JP2020562156 A JP 2020562156A JP 2020562156 A JP2020562156 A JP 2020562156A JP 2021523129 A5 JP2021523129 A5 JP 2021523129A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- combination
- hcv
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669007P | 2018-05-09 | 2018-05-09 | |
| US62/669,007 | 2018-05-09 | ||
| PCT/US2019/031459 WO2019217643A1 (en) | 2018-05-09 | 2019-05-09 | Combination therapy for treatment of hcv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523129A JP2021523129A (ja) | 2021-09-02 |
| JP2021523129A5 true JP2021523129A5 (enExample) | 2022-05-17 |
| JP7381493B2 JP7381493B2 (ja) | 2023-11-15 |
Family
ID=66641500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562156A Active JP7381493B2 (ja) | 2018-05-09 | 2019-05-09 | Ｈｃｖを治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11752166B2 (enExample) |
| EP (1) | EP3790542B1 (enExample) |
| JP (1) | JP7381493B2 (enExample) |
| KR (1) | KR20210018806A (enExample) |
| CN (1) | CN112203652A (enExample) |
| AU (1) | AU2019265740A1 (enExample) |
| CA (1) | CA3096916A1 (enExample) |
| MX (1) | MX2020011912A (enExample) |
| TW (1) | TWI833753B (enExample) |
| WO (1) | WO2019217643A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022015982A1 (en) * | 2020-07-17 | 2022-01-20 | The Regents Of The University Of California | Compositions and methods for treating viral infections |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| US6881741B2 (en) | 2001-06-11 | 2005-04-19 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| DE60221627D1 (de) | 2001-12-21 | 2007-09-20 | Virochem Pharma Inc | Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren |
| US20040192707A1 (en) | 2002-12-10 | 2004-09-30 | Laval Chan Chun Kong | Compounds and methods for the treatment or prevention of Flavivirus infections |
| KR101058696B1 (ko) | 2002-12-10 | 2011-08-22 | 바이로켐 파마 인코포레이티드 | 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법 |
| MXPA05006196A (es) | 2002-12-10 | 2006-01-27 | Virochem Pharma Inc | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| WO2006119646A1 (en) | 2005-05-13 | 2006-11-16 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| WO2008017688A1 (en) | 2006-08-11 | 2008-02-14 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti-viral agents |
| WO2008043791A2 (en) | 2006-10-13 | 2008-04-17 | Smithkline Beecham Corporation | Thiophene derivatives for treating hepatitis c |
| JP5290186B2 (ja) | 2006-11-15 | 2013-09-18 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染症の治療または予防用のチオフェン類似体 |
| US20090274655A1 (en) | 2006-11-17 | 2009-11-05 | Richard Martin Grimes | 2-carboxy thiophene derivatives as anti viral agents |
| GB0707092D0 (en) | 2007-04-12 | 2007-05-23 | Smithkline Beecham Corp | Compounds |
| GB0712393D0 (en) | 2007-06-26 | 2007-08-01 | Smithkline Beecham Corp | Compounds |
| HK1214270A1 (zh) * | 2012-10-29 | 2016-07-22 | 共晶制药股份有限公司 | 用於治療病毒感染和癌症的嘧啶核苷及其單磷酸酯前藥 |
| BR112016023833A2 (pt) * | 2014-04-15 | 2017-10-10 | Cocrystal Pharma Inc | compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c |
| TWI731854B (zh) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Ｃ型肝炎病毒聚合酶之抑制劑 |
| US9937160B2 (en) * | 2015-07-16 | 2018-04-10 | Cipla (UK) Limited | Thienopyridine derivative for the treatment of hepatitis C infections |
-
2019
- 2019-05-09 KR KR1020207033655A patent/KR20210018806A/ko not_active Ceased
- 2019-05-09 MX MX2020011912A patent/MX2020011912A/es unknown
- 2019-05-09 TW TW108116038A patent/TWI833753B/zh active
- 2019-05-09 US US17/047,209 patent/US11752166B2/en active Active
- 2019-05-09 AU AU2019265740A patent/AU2019265740A1/en not_active Abandoned
- 2019-05-09 CN CN201980030086.3A patent/CN112203652A/zh active Pending
- 2019-05-09 EP EP19726259.5A patent/EP3790542B1/en active Active
- 2019-05-09 CA CA3096916A patent/CA3096916A1/en active Pending
- 2019-05-09 JP JP2020562156A patent/JP7381493B2/ja active Active
- 2019-05-09 WO PCT/US2019/031459 patent/WO2019217643A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521118A5 (enExample) | ||
| JP2004509061A5 (enExample) | ||
| JP2008518943A5 (enExample) | ||
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| JP2009535352A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| JP2013529627A5 (enExample) | ||
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| WO1995003056A1 (en) | Hepatitis c virus proliferation inhibitor | |
| JP2013522302A5 (enExample) | ||
| JP2010503396A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| JP2017514911A5 (enExample) | ||
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| Sun et al. | Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives | |
| JP2002528502A5 (enExample) | ||
| JP2018532797A5 (enExample) | ||
| CN102083435A (zh) | 特拉匹韦给药方案 | |
| JP2021523129A5 (enExample) | ||
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| JP2024525164A5 (enExample) | ||
| JP2023518390A (ja) | ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 | |
| JP2021522802A5 (enExample) |